Quantcast

Latest Amides Stories

2014-06-19 23:17:47

German drugmaker Boehringer Ingelheim has offered to settle almost 4,000 Pradaxa lawsuits in the United States. The Pradaxa blood thinner is alleged to have cause injuries and fatalities. WINSTON-SALEM, NC (PRWEB) June 19, 2014 Mike Lewis Attorneys, a product liability firm in Tennessee, is reviewing and investigating the impact of Boehringer Ingelheim’s $650 million settlement offer. If successful, the offer would settle more than 4,000 pending Pradaxa claims in the United States. In...

2014-06-17 23:03:04

New research study “Antibiotics Partnering Terms and Agreements” worked out by CurrentPartnering is now available at MarketPublishers.com. London, UK (PRWEB) June 17, 2014 Antibiotics are antimicrobial compounds, used to treat a broad range of various bacterial infections in humans as well as animals and plants. Antibiotics have saved countess lives since their discovery. Antibiotics are effective against certain fungal and bacterial infections and are also used a treatment for...

2014-06-05 23:01:35

A recent settlement announcement involving Pradaxa has been announced by the manufacture, Boehringer Ingelheim. Toledo, Ohio (PRWEB) June 05, 2014 Boehringer Ingelheim, the manufacturing company of the blood thinning drug Pradaxa, announced in May 2014 a $650 million settlement deal this week to settle approximately 4,000 state and federal lawsuits. Reported by TIME May 2014, Pradaxa was approved by the US Food and Drug Administration (FDA) in October 2010, Pradaxa is formulated for use...

2014-06-02 08:32:06

Results show adding LBH589 to bortezomib and dexamethasone significantly improved PFS by 37%, meeting Phase III study primary endpoint1 EAST HANOVER, N.J., June 2, 2014 /PRNewswire/ -- Novartis today presented results from a pivotal Phase III trial showing a 37% improvement in progression-free survival (PFS) when using the investigational compound LBH589 (panobinostat) in combination with bortezomib[*] and dexamethasone compared to treatment with the same regimen with placebo in patients with...

2014-06-02 08:29:12

Can-Fite's CF102 has FDA's Orphan Drug Designation for the treatment of advanced hepatocellular carcinoma PETACH TIKVA, Israel, June 2, 2014 /PRNewswire/ -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the U.S. FDA has agreed with the Company's study protocol for its Phase II clinical trial of CF102 for the treatment of advanced...

2014-05-29 23:15:58

Boehringer Ingelheim Agrees to Pay $650 Million To Settle 4,000 Pradaxa Lawsuit That Allege Internal Bleeding After Taking The Prescription Medication. Columbus, OH (PRWEB) May 29, 2014 Wright & Schulte LLC, an experienced personal injury law firm representing plaintiffs in Pradaxa lawsuits pending in federal court, reports that Boehringer Ingelheim has agreed to pay $650 million to settle Pradaxa lawsuits filed on behalf of plaintiffs who allegedly experienced serious internal...

2014-05-28 23:02:26

The Firm is evaluating Pradaxa bleeding claims on behalf of individuals who allegedly suffered life-threatening episodes of internal hemorrhaging due to their use of Pradaxa. New York, New York (PRWEB) May 28, 2014 As Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/) continue to mount in federal court, Bernstein Liebhard LLP notes that the manufacturer of the blood thinner has acknowledged that a number of serious bleeding events were omitted from the original report on a clinical...

2014-05-28 08:31:29

RIDGEFIELD, Conn., May 28, 2014 /PRNewswire/ -- Boehringer Ingelheim (BI) announced today that it has reached a comprehensive settlement of state and federal cases in the U.S. litigation regarding Pradaxa® (dabigatran etexilate mesylate) in the amount of $650 million. "Time and again, the benefits and safety of PRADAXA have been confirmed," said Desiree Ralls-Morrison, senior vice president and general counsel, Boehringer Ingelheim USA Corporation. "BI stands resolutely behind PRADAXA and...

2014-05-27 16:25:23

New Data Reinforces Commitment to Personalized Medicine and Highlights Advances in Immunotherapy Platform THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., May 27, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., today announced data from several studies of both pipeline and marketed products will be presented at the 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 30-June 3 in Chicago. The research that will...

2014-05-23 23:09:43

Ashley Brittain Landers of Schlichter, Bogard & Denton, LLP reports that the FDA has issued a new safety announcement regarding the increased risk of major gastrointestinal (GI) bleeding associated with Pradaxa in comparison to warfarin. The attorneys at Schlichter, Bogard & Denton, LLP are offering free and confidential case reviews to those who allege to have been injured after using Pradaxa. St. Louis, MO (PRWEB) May 23, 2014 On May 13, 2014, the FDA issued a Safety...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related